Roche GM's tough line on Aussie TV

Roche Australia General Manager Nic Horridge appeared on ABC TV last night branding a Government-requested price cut for the company's MS drug as "unrealistic" and "unreasonable" and warned it threatens the sustainability of business models that allow innovative medicines to reach Australia.

In an interview on the 7.30 Report, Horridge delivered a frank warning that the proposed price cut for Ocrevus - believed to be an eye-watering 40 per cent -  was simply impossible.

Alongside Ocrevus, Novartis' Kesimpta is also subject to the same price cut following the January PBS listing of a much cheaper MS drug, Neuraxpharm's Briumvi.